Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
November 2013

Citalopram, the QT Interval, and the FDA's Warning
The relationship between citalopram (Celexa and others) dose and cardiac adverse events is still not completely understood.

IV Sodium Nitroprusside for Schizophrenia?
In a small trial of patients with schizophrenia, a single infusion of sodium nitroprusside was significantly superior to placebo in improving symptoms.

Aripiprazole IM Depot
An extended-release long-acting intramuscular injectable formulation of aripiprazole (Abilify Maintena) is now available in the United States.

In Brief
Use of Tricyclic or Selective Serotonin Reuptake Inhibitor Antidepressants Does Not Increase Bone Loss in Women; Smoking during Pregnancy Is Associated with Conduct Disorders in Offspring

Premature Death in Schizophrenia
In a study of deceased patients with schizophrenia, the three leading causes of death were cardiovascular disease, suicide, and drug toxicity.

Aripiprazole IM Depot

November 2013

The FDA recently approved a long-acting intramuscular (IM) injectable formulation of aripiprazole: Abilify Maintena. An extended-release preparation labeled for once-monthly treatment of schizophrenia, it is the fourth second-generation antipsychotic for which there is now a long-acting parenteral…

To view the rest of this article, please: